The estimated Net Worth of Stephen H Rusckowski is at least $63.8 Millón dollars as of 25 May 2022. Mr. Rusckowski owns over 24,891 units of Quest Diagnostics stock worth over $53,697,936 and over the last 13 years he sold DGX stock worth over $0. In addition, he makes $10,118,500 as Chairman of the Board, President y Chief Executive Officer at Quest Diagnostics.
Sign up
Mr. Rusckowski DGX stock SEC Form 4 insiders trading
Stephen has made over 15 trades of the Quest Diagnostics stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 24,891 units of DGX stock worth $2,326,313 on 25 May 2022.
The largest trade he's ever made was exercising 359,874 units of Quest Diagnostics stock on 23 May 2022 worth over $33,903,730. On average, Stephen trades about 24,830 units every 53 days since 2012. As of 25 May 2022 he still owns at least 349,687 units of Quest Diagnostics stock.
You can see the complete history of Mr. Rusckowski stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Stephen Rusckowski biography
Stephen H. Rusckowski serves as Chairman of the Board, President, Chief Executive Officer of the Company. Mr. Rusckowski joined the Company in May 2012 as Chief Executive Officer and President and became Chairman of the Board on January 1, 2017. From October 2006 until he joined the Company, he was Chief Executive Officer of Philips Healthcare, the largest unit of Royal Philips Electronics, and a member of the Board of Management of Royal Philips Electronics and its Executive Committee. Previously, he was CEO of the Imaging Systems business of Royal Phillips Electronics. Before joining Philips in 2001, Mr. Rusckowski held numerous management positions with the healthcare division of Hewlett-Packard/Agilent Technologies. Mr. Rusckowski has been a director of the Company since May 2012. He was a director of Xerox Corporation from February 2015 to 2018, and a director of Covidien plc from December 2013 to January 2015. Mr. Rusckowski served as Chairman of the American Clinical Laboratory Association from 2014 to 2017.
What is the salary of Stephen Rusckowski?
As the Chairman of the Board, President y Chief Executive Officer of Quest Diagnostics, the total compensation of Stephen Rusckowski at Quest Diagnostics is $10,118,500. There are no executives at Quest Diagnostics getting paid more.
How old is Stephen Rusckowski?
Stephen Rusckowski is 62, he's been the Chairman of the Board, President y Chief Executive Officer of Quest Diagnostics since 2017. There are 6 older and 13 younger executives at Quest Diagnostics. The oldest executive at Quest Diagnostics, Inc. is Gail Wilensky, 76, who is the Independent Director.
Insiders trading at Quest Diagnostics
Over the last 21 years, insiders at Quest Diagnostics have traded over $67,426,608 worth of Quest Diagnostics stock and bought 34,000 units worth $1,910,090 . The most active insiders traders include Plc Gsk, James F Iii Flaherty y Jeffrey M Leiden. On average, Quest Diagnostics executives and independent directors trade stock every 19 days with the average trade being worth of $3,750,703. The most recent stock trade was executed by Michael E Prevoznik on 29 August 2024, trading 32,551 units of DGX stock currently worth $3,118,386.
What does Quest Diagnostics do?
quest diagnostics (nyse: dgx) empowers people to take action to improve health outcomes. derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. quest annually serves one in three adult americans and half the physicians and hospitals in the united states, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. the company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (ap) services, & interpretive consultation through its medical & scientific staff of about 900 m.d.s & ph.d.s. the company reported 2014 revenues of $7.4 billion. quest diagnostics offers the most extensive clinical testing network in the u.s., with laborator
What does Quest Diagnostics's logo look like?
Complete history of Mr. Rusckowski stock trades at Baxter International, Quest Diagnostics, Tenet Healthcare y Xerox Corp
Quest Diagnostics executives and stock owners
Quest Diagnostics executives and other stock owners filed with the SEC include:
-
Stephen Rusckowski,
Chairman of the Board, President, Chief Executive Officer -
Manuel Mendez,
Executive Officer -
Stephen H. Rusckowski,
Chairman, Pres & CEO -
Mark Guinan,
Chief Financial Officer, Executive Vice President -
James Davis,
Executive Vice President, General Diagnostics -
Carrie Manner,
Senior Vice President - Advanced Diagnostics -
Catherine Doherty,
Senior Vice President, Group Executive - Clinical Franchise Solutions and Marketing -
Michael Prevoznik,
Senior Vice President, General Counsel -
James E. Davis,
Exec. VP of Gen. Diagnostics -
Carrie Eglinton Manner,
Sr. VP of Advanced Diagnostics -
Daniel Stanzione,
Lead Independent Director -
Gary Pfeiffer,
Independent Director -
Denise Morrison,
Independent Director -
Gail Wilensky,
Independent Director -
Timothy Main,
Independent Director -
Timothy Ring,
Independent Director -
Vicky Gregg,
Independent Director -
Helen Torley,
Independent Director -
Wright Lassiter,
Independent Director -
Michael E. Prevoznik,
Sr. VP & Gen. Counsel -
Mark J. Guinan,
Exec. VP & CFO -
Gary D. Samuels,
VP of Corp. Communications -
Timothy Sharpe,
VP of Compliance -
Shawn C. Bevec,
VP of Investor Relation -
Gabrielle Wolfson,
Sr. VP and Chief Information & Digital Officer -
Michael J. Deppe,
VP, Corp. Controller & Chief Accounting Officer -
Robert B Carter,
Director -
Jeffrey M Leiden,
Director -
Jenne K Britell,
Director -
Robert A Klug,
VP, Corporate Controller -
Everett Cunningham,
SVP, Commercial -
John B Ziegler,
Director -
Jon R Cohen,
SVP and Chief Medical Officer -
William F Buehler,
Director -
John B. Haydon,
SVP, Operations -
Kathy Ordonez,
SVP, Discovery & Development -
Robert Hagemann,
Corp VP & Chief Fin Officer -
Surya N Mohapatra,
President & COO -
Joan Elizabeth Miller,
Sr VP -Pathology& HospServices -
John C Md Baldwin,
Director -
Wayne R. Simmons,
Vice President, Operations -
Rosanne Haggerty,
Director -
Plc Gsk,
10% owner -
Thomas W Ii Grant,
Executive Officers -
William R Grant,
Director -
Thomas F Bongiorno,
Vice President and Controller -
James F Iii Flaherty,
Director -
David M Zewe,
Sr. VP -Diagnostic Testg Ops -
Robert E Peters,
Vice President, Sales & Mktg. -
Kenneth W/Nj Freeman,
Chairman, Chief Exec Officer -
Mary A Cirillo,
Director -
Kenneth D Brody,
Director -
Gerald C Marrone,
Sr. VP, Administration -
Luis Diaz,
Director -
Tracey Doi,
Director -
Michael J Deppe,
SVP, Corp. Controller & CAO -
Sam Samad,
Executive Vice President & CFO -
Patrick Plewman,
SVP for Diagnostic Services -
Karthik Kuppusamy,
SVP, Clinical Solutions -
J. E. Davis,
CEO and President -
Mark E Delaney,
SVP & Chief Commercial Officer -
Mark A Gardner,
SVP of Molecular Gen & Oncol